Medicinova Form 4: Hideki Nagao Receives 20k Options, Neutral Impact

Rhea-AI Filing Summary

Form 4 filed for Medicinova, Inc. (MNOV) discloses that director Hideki Nagao received an option grant for 20,000 shares of common stock on 16 June 2025 at an exercise price of $1.26 per share. The options expire on 16 June 2035 and vest in four equal tranches on 30 Sep 2025, 31 Dec 2025, 31 Mar 2026 and 30 Jun 2026, contingent upon continued board service. No shares were sold or otherwise disposed of, and Nagao’s beneficial ownership in derivative securities increases to 20,000 options following this single transaction. The filing represents routine equity-based compensation and does not indicate any change in company fundamentals or insider sentiment beyond standard alignment incentives.

Insights

Financial Analyst

TL;DR: Routine option grant; immaterial volume; neutral impact.

This Form 4 documents a standard director option award—20,000 options at $1.26 strike, roughly at-the-money for MNOV. The total notional value is modest and vests over one year, typical of small-cap governance practices. No open-market purchase or sale occurred, so there is no immediate signal about insider conviction. Because the award size is small relative to outstanding shares and market cap, the filing is unlikely to influence valuation, liquidity, or near-term trading dynamics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nagao Hideki

(Last) (First) (Middle)

C/O MEDICINOVA,INC.

4275 EXECUTIVE SQUARE, SUITE 300

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MEDICINOVA INC [ MNOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.26	06/17/2025		A		20,000		(1)	06/16/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vests in four equal installments on September 30, 2025, December 31, 2025, March 31, 2026 and June 30,2026, subject to continued service with the Company.

	/s/ Yuichi Iwaki, attorney-in-fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Medicinova (MNOV) disclose in the latest Form 4?

Director Hideki Nagao received 20,000 stock options at a $1.26 exercise price on 16 Jun 2025.

How many shares are covered by the new option grant to Hideki Nagao?

The grant covers 20,000 shares of MNOV common stock.

What is the vesting schedule for the MNOV director options?

The options vest in four equal installments on 30 Sep 2025, 31 Dec 2025, 31 Mar 2026 and 30 Jun 2026.

What is the expiration date of the newly granted MNOV options?

The options expire on 16 June 2035.

Did the MNOV director sell or buy common shares in the open market?

No. The filing reflects an option grant only; there were no open-market purchases or sales.